Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02541604 · OUTCOME

PFS as Determined by the Investigator Using irRC for Participants With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors · Source last updated 2020-02-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)

Analysis population: Included safety-evaluable population, defined as patients who received any amount of study drug.

Groups in this outcome

Cohort 2

Participants with hodgkin lymphoma

Cohort 4

Participants with non-hodgkin's lymphoma

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cohort 29
Cohort 43

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Cohort 26.5Not reported2.6NAMore than 50% patient was censored.
Cohort 43.7Not reported1.4NAMore than 50% patient was censored.
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        More than 50% patient was censored.
        group Id
        OG000
        lower Limit
        2.6
        upper Limit
        NA
        value
        6.5
      2. comment
        More than 50% patient was censored.
        group Id
        OG001
        lower Limit
        1.4
        upper Limit
        NA
        value
        3.7
denoms
  1. counts
    1. group Id
      OG000
      value
      9
    2. group Id
      OG001
      value
      3
    units
    Participants
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants with hodgkin lymphoma
    id
    OG000
    title
    Cohort 2
  2. description
    Participants with non-hodgkin's lymphoma
    id
    OG001
    title
    Cohort 4
param Type
MEDIAN
population Description
Included safety-evaluable population, defined as patients who received any amount of study drug.
reporting Status
POSTED
time Frame
Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)
title
PFS as Determined by the Investigator Using irRC for Participants With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice